Current status and future prospects of chemotherapy for advanced hepatocellular carcinoma

Clinical Journal of Gastroenterology

Volumn 9, Issue 4, 2016, Pages 184-190

  Moriguchi, Michihisa ^a   Umemura, Atsushi ^a   Itoh, Yoshito ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Chemotherapy; Hepatic arterial infusion chemotherapy; Hepatocellular carcinoma; Immune checkpoint inhibitor; Molecular targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BRIVANIB; CABOZANTINIB; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; IMMUNE CHECKPOINT INHIBITOR; LENVATINIB; LINIFANIB; NIVOLUMAB; OXALIPLATIN; RAMUCIRUMAB; REGORAFENIB; SORAFENIB; SUNITINIB; TIVANTINIB; TS 1; UNCLASSIFIED DRUG; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; FUTUROLOGY; HUMAN; LIVER CELL CARCINOMA; MOLECULARLY TARGETED THERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMIC THERAPY; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; HEPATIC ARTERY; IMMUNOTHERAPY; INTRAARTERIAL DRUG ADMINISTRATION; LIVER NEOPLASMS; PROCEDURES; TRENDS;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; HEPATIC ARTERY; HUMANS; IMMUNOTHERAPY; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; NIACINAMIDE; PHENYLUREA COMPOUNDS;

EID: 84978096991     PISSN: 18657257     EISSN: 18657265     Source Type: Journal    
DOI: 10.1007/s12328-016-0670-7     Document Type: Review

References (48)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
2. Kudo M, Matsui O, Izumi N, Liver Cancer Study Group of Japan, et al. JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the Liver Cancer Study Group of Japan. Liver Cancer. 2014;2014(3):458–68.
3. Belghiti J, Fuks D. Liver resection and transplantation in hepatocellular carcinoma. Liver Cancer. 2012;1:71–82.
4. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002;35:519–24.
5. Llovet JM, Real MI, Montaña X, Barcelona Liver Cancer Group, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734–9.
6. Takayasu K, Arii S, Kudo M, et al. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. J Hepatol. 2012;56:886–92.
7. Ikeda M, Arai Y, Park SJ, Japan Interventional Radiology in Oncology Study Group (JIVROSG), Korea Interventional Radiology in Oncology Study Group (KIVROSG), et al. Prospective study of transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: an Asian cooperative study between Japan and Korea. J Vasc Interv Radiol. 2013;24:490–500.
8. Lammer J, Malagari K, Vogl T, PRECISIONV Investigators, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISIONV study. Cardiovasc Interv Radiol. 2010;33:41–52.
9. Golfieri R, Giampalma E, Renzulli M, PRECISION ITALIA STUDY GROUP, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer. 2014;111:255–64.
10. Llovet JM, Ricci S, Mazzaferro V, SHARP Investigators Study Group, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.
11. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.
12. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099–109.
13. Chang YS, Adnane J, Trail PA, et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol. 2007;59:561–74.
14. Raoul JL, Bruix J, Greten TF, et al. Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. J Hepatol. 2012;56:1080–8.
15. Bruix J, Takayama T, Mazzaferro V, STORM Investigators, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16:1344–54.
16. Lencioni R, Llovet JM, Han G, et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial. J Hepatol. 2016;64:1090–8.
17. Kudo M, Imanaka K, Chida N, et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer. 2011;47:2117–27.
18. Ogasawara S, Chiba T, Ooka Y, et al. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization. Oncology. 2014;87:330–41.
19. Arizumi T, Ueshima K, Minami T, et al. Effectiveness of sorafenib in patients with transcatheter arterial chemoembolization (TACE) refractory and intermediate-stage hepatocellular carcinoma. Liver Cancer. 2015;4:253–62.
20. Park JW, Finn RS, Kim JS, et al. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2011;17:1973–83.
21. Johnson PJ, Qin S, Park JW, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol. 2013;31:3517–24.
22. Llovet JM, Decaens T, Raoul JL, et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol. 2013;31:3509–16.
23. Toh HC, Chen PJ, Carr BI, et al. Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma. Cancer. 2013;119:380–7.
24. Cainap C, Qin S, Huang WT, et al. Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol. 2015;33:172–9.
25. Cheng AL, Kang YK, Lin DY, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol. 2013;31:4067–75.
26. Zhu AX, Rosmorduc O, Evans TR, Ross PJ, Santoro A, Carrilho FJ, et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2015;33:559–66.
27. Ikeda K, Kumada H, Kudo M, et al. Phase I/II trial of lenvatinib (E7080), a multi-targeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC). Ann Oncol. 2012;23(Suppl 9; abstr 737P).
28. Zhu AX, Kudo M, Assenat E, et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA. 2014;312:57–67.
29. Verslype C, Cohn AL, Kelley RK, et al. Activity of cabozantinib (XL184) in hepatocellular carcinoma: Results from a phase II randomized discontinuation trial (RDT). J Clin Oncol. 2012;30(Suppl; abstr 4007).
30. Zhu AX, Park JO, Ryoo BY, REACH Trial Investigators, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015;16:859–70.
31. Santoro A, Rimassa L, Borbath I, et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase2 study. Lancet Oncol. 2013;14:55–63.
32. Bruix J, Tak WY, Gasbarrini A, et al. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur J Cancer. 2013;49:3412–9.
33. Qin S, Bai Y, Lim HY, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol. 2013;31:3501–8.
34. Kudo M, Moriguchi M, Numata K, et al. A randomized, double-blind, placebo-controlled phase III study of S-1 in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE). J Clin Oncol. 2015; 33(Suppl; abstr 4018).
35. Kudo M, Okusaka T, Kaneko S, et al. Identification of a high-response patient population to S-1 via predictive enrichment strategy analysis of the S-CUBE phase III trial. J Clin Oncol. 2016; 34(Suppl 4S; abstr 229).
36. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54.
37. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23–34.
38. Borghaei H, Paz-Ares L, Horn L, et al. nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–39.
39. Gao Q, Wang XY, Qiu SJ, et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res. 2009;15:971–9.
40. Gabrielson A, Wu Y, Wang H, et al. Intratumoral CD3 and CD8 T-cell densities associated with relapse-free survival in HCC. Cancer Immunol Res. 2016;4:419–30.
41. El-Khoueiry AB, Melero I, Crocenzi TS, et al. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. J Clin Oncol. 2015; 33(Suppl; abstr LBA101).
42. Yoshikawa M, Ono N, Yodono H, Ichida T, Nakamura H. Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma. Hepatol Res. 2008;38:474–83.
43. Ando E, Tanaka M, Yamashita F, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer. 2002;95:588–95.
44. Ueshima K, Kudo M, Takita M, et al. Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma. Oncology. 2010;78:148–53.
45. Yamashita T, Arai K, Sunagozaka H, et al. Randomized, phase II study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma. Oncology. 2011;81:281–90.
46. Obi S, Yoshida H, Toune R, et al. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer. 2006;106:1990–7.
47. Ikeda M, Shimizu S, Sato T, et al. Sorafenib plus intra-arterial cisplatin versus sorafenib alone in patients with advanced hepatocellular carcinoma: a randomized phase II trial. J Clin Oncol. 2015; 33(Suppl; abstr 4076).
48. Kudo M, Ueshima K, Yokosuka O, et al. Prospective randomized controlled phase III trial comparing the efficacy of sorafenib versus sorafenib in combination with low-dose cisplatin/fluorouracil hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma. J Hepatol. 2016;64(Suppl 2; abstr LB04).